Sun Yat-sen University Cancer Center at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Sun Yat-sen University Cancer Center takes part in 19 sessions at ESMO 2026 in Madrid. Its program centres on clinical trial results for new antibody-drug conjugates and multi-target antibodies in cervical, HER2-positive gastric and colorectal cancers. Other sessions cover neoadjuvant immunotherapy for penile cancer, a Bruton's tyrosine kinase inhibitor in B-cell lymphoma and new agents for breast cancer in China.

Organization

ESMO 2026 Attendance

Sun Yat-sen University Cancer Center

Guangzhou, China

sysucc.org.cn

Cancer centre & hospital

Cancer hospital, research institute and state key oncology laboratory of Sun Yat-sen University, a public university in Guangzhou, China.

Abstract

Fri Oct 23
13:30–13:35

1209RO - Neoadjuvant toripalimab combined with chemotherapy for locally advanced penile squamous cell carcinoma: A multicenter prospective, single-arm, phase II clinical trial

Rapid oral: Genitourinary tumours, prostate, penile and testils

Genitourinary cancersGastrointestinal cancers

Abstract

Fri Oct 23
13:50–14:00

LBA27 - APEX-Breast01: TQB2102 versus chemotherapy in HER2-low recurrent or metastatic breast cancer (r/m BC) : Results from a randomized phase 3 study

Proffered paper 1: Breast cancer, early and advanced stage

Breast cancer

Abstract

Fri Oct 23
14:25–14:35

1949O - Phase 1b/2 study of anti-CCR8 antibody QLP2117 plus anti-PD-1 antibody QL2107 in patients (pts) with advanced solid tumors

Proffered paper: Investigational immunotherapy

Chair

Fri Oct 23
16:15–17:45

Rapid oral 1: Gastrointestinal tumour, upper digestive

with Instituto do Câncer do Estado de São Paulo (ICESP), Maria Sklodowska-Curie National Research Institute of Oncology

Gastrointestinal cancers

Abstract

Fri Oct 23
16:20–16:25

1244RO - SHR-A2102, a novel nectin-4-targeted antibody-drug conjugate, in patients with recurrent or metastatic cervical cancer: results from a phase 2 study

Rapid oral 1: Gynaecological cancers

Gynaecological cancers

Abstract

Fri Oct 23
16:25–16:30

2876RO - TQB2102, a Novel HER2 Bispecific Antibody-Drug Conjugate, Combined with Bemotrizumab with or without Capecitabine as First-Line Therapy for HER2-Positive Advanced Gastric/Gastroesophageal Junction Cancer: A Phase II Study

Rapid oral 1: Gastrointestinal tumour, upper digestive

Gastrointestinal cancers

Abstract

Fri Oct 23
16:57–17:09

Invited Discussant 2877RO, 2878RO and LBA81

Rapid oral 1: Gastrointestinal tumour, upper digestive

Gastrointestinal cancers

Abstract

Sat Oct 24
09:15–09:25

1457O - First Report of a Phase Ib Study of Rocbrutinib, a Fourth-Generation Bruton’s Tyrosine Kinase Inhibitor, Combined with R-CHOP in Patients with Previously Untreated B-Cell Lymphoma

Proffered Paper: Haematological malignancies

Haematological malignancies

Abstract

Sat Oct 24
09:22–09:27

1953RO - Safety and efficacy of CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, in metastatic colorectal cancer (mCRC): Results from a phase 1/2 study

Rapid oral: Investigational immunotherapy

Abstract

Sat Oct 24
09:22–09:27

2631RO - First-line BAT8008 (TROP2-ADC) plus BAT1308 (anti-PD-1) for advanced NSCLC: Results from a multicenter phase 2 study

Rapid oral 1: NSCLC, metastatic

Lung & thoracic cancers

Abstract

Sat Oct 24
14:55–15:05

1000O - HS-20122, a Novel EGFR/cMET Bispecific Antibody Drug Conjugate, in Advanced Solid Tumors

Proffered paper: Developmental therapeutics

Abstract

Sat Oct 24
15:47–15:57

1240O - Iparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): Results from a double-blind, randomized, placebo-controlled phase 3 trial

Proffered paper: Gynaecological cancers

Gynaecological cancers

Abstract

Sun Oct 25
08:35–08:40

LBA33 - Safety and efficacy of GFH276 monotherapy in previously treated RAS-mutated advanced solid tumors

Rapid oral: Developmental therapeutic

Abstract

Sun Oct 25
08:40–08:50

LBA43 - Tam-Peli versus chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): a multicenter, randomized, open-label, phase 3 study (TAISHAN-301)

Proffered paper: Head and neck cancer

Sarcoma, CNS, head & neck and rare cancers

Abstract

Sun Oct 25
11:03–11:13

LBA67 - Final OS analysis of sacituzumab tirumotecan (sac-TMT) versus platinum-based chemotherapy in EGFR-mutated non-small cell lung cancer (NSCLC) after progression on EGFR-TKI: phase III OptiTROP-Lung04 study

Proffered paper 1: NSCLC, metastatic

Lung & thoracic cancers

Abstract

Sun Oct 25
11:09–11:14

LBA61 - Disitamab Vedotin in locally advanced or metastatic extramammary Paget’s disease with HER2 high expression: a prospective, single-arm phase II trials (Formula-10)

Rapid oral: Melanoma and other skin tumours

Melanoma & skin cancers

Abstract

Sun Oct 25
17:18–17:30

LBA7 - CLARITY-Gastric 01 (CG-01): a Phase 3 study of sonesitatug vedotin (Sone-Ve) in second or later-line (2L+) advanced or metastatic Claudin 18.2 (CLDN18.2) positive gastroesophageal carcinoma (GEC)

Presidential Symposium II

Lung & thoracic cancersGastrointestinal cancers

Abstract

Mon Oct 26
08:57–09:02

3720RO - Nab-paclitaxel plus pegylated liposomal doxorubicin in advanced or unresectable malignant vascular tumors: results from a phase II study

Rapid oral: Sarcoma

Sarcoma, CNS, head & neck and rare cancers

Abstract

Mon Oct 26
09:22–09:32

LBA71 - PANKU-Lung01: Randomized Phase III Study of Izalontamab Brengitecan (iza-bren) in EGFR-Mutant Non-squamous Non‑Small Cell Lung Cancer (NSCLC) After Progression on a Third Generation EGFR TKI

Proffered paper 2: NSCLC, metastatic

Lung & thoracic cancers

Abstract

Mon Oct 26
11:07–11:12

4156RO - Ivonescimab plus chemotherapy as first-line treatment in recurrent/metastatic thymic carcinoma: interim results from the iTHYM phase II study

Rapid oral: Non-metastatic NSCLC and other thoracic malignancies

Lung & thoracic cancers

Talk

Mon Oct 26
15:00–15:15

Innovations in breast cancer in China: Novel agents and emerging approaches

ESMO-CSCO: Navigating the development pathways of cancer therapeutics -From China to the world

Instantly find 20 buyers from Sun Yat-sen University Cancer Center

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction